Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans

Research output: Article

7 Citations (Scopus)

Abstract

The pharmacokinetics of 2β,16β-bis-(4'-dimethyl-1'-piperazino)-3α,17β-diacetoxy-5α-androstane dibromide (pipecurium bromide, Arduan®), a new non-depolarizing neuromuscular blocking agent, was studied in surgical patients. Plasma concentration-time curves of pipecurium bromide were evaluated by fitting the data to a bi-exponential equation. The average half-lives were T(α)( 1/2 ) = 4.1±1.4 (n = 8) and T(β)( 1/2 ) = 44±7 (n = 8) min. The pharmacokinetic parameters of pipecurium bromide were found as follows: apparent distribution volume Vβ = 261±28 (n = 8) ml/kg, plasma clearance Cl = 320±55 (n = 8) ml/min. The microconstants of two-compartment open models were also calculated.

Original languageEnglish
Pages (from-to)1754-1756
Number of pages3
JournalArzneimittel-Forschung/Drug Research
Volume31
Issue number10
Publication statusPublished - jan. 1 1981

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans'. Together they form a unique fingerprint.

  • Cite this